What emerged through such discussions was not optimism nor was it pessimism, but clarity. The consensus was striking in its consistency across sessions. JPM 2026 signalled genuine recovery – but not ...

Get the latest federal technology news delivered to your inbox. The congressional working group on the national security ramifications of biotechnology is angling to publish and deliver new policy ...

Biotechnology is no longer distant science fiction; it’s already a growing force in both national security and local economies. It affects everything from how much you pay at the pharmacy to whether ...

The beauty industry has long harnessed biotechnology — namely taking the most powerful skincare ingredients in nature and recreating them using science to make them more potent, stable, ...

BioTechAnalyzer is a research and analytics platform focused on making complex FDA-related biotechnology information clear, accessible, and actionable for investors. The platform focuses on late-stage ...

Slow rolling chaos at the FDA and its effects on drug approvals. How to think about risk when investing in biotech. A review of results from DNA researcher Twist Bioscience. Don't wait! Be sure to get ...

Recognition underscores ValGenesis’ pioneering leadership and continued innovation in digital validation and AI-enabled lifecycle management. ValGenesis, the market leader in enterprise validation ...

Forbes contributors publish independent expert analyses and insights. I write about finance, innovation, climate and sustainability Europe’s next wave of biotech innovation could determine how the ...

This exclusive Cogs of War interview is with Diane DiEuliis, a distinguished research fellow at National Defense University focused on emerging biological technologies, biodefense, and preparedness ...

Discover the best biotech ETFs to diversify your portfolio, gain exposure to cutting-edge biotech innovations, and reduce risk in a volatile sector.

In this podcast, Motley Fool analysts Karl Thiel, Tom King, and Tim Beyers discuss: Slow rolling chaos at the FDA and its effects on drug approvals. How to think about risk when investing in biotech.